Skip to main content
Quest Diagnostics Home

Prenatal Cell-Free DNA Screening for 22q11.2 Deletion Syndrome: Positive Predictive Value Estimates From a Large US Clinical Laboratory

ACMG 2020: Annual Clinical Genetics Meeting
Virtual [in-person conference canceled], March 17-21, 2020

Prenatal Cell-Free DNA Screening for 22q11.2 Deletion Syndrome: Positive Predictive Value Estimates from a Large US Clinical Laboratory

Authors: Kahl K, Guy C, Karamata N, Owen R, Anderson B, Zhang K, Lacbawan FL, Alagia DP

Specialties: genetics, women's health, OB/GYN

Download key summary

Our company

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.